Nektar's REZOLVE-AD Phase 2b Study Meets Primary Endpoint In Atopic Dermatitis
(RTTNews) - Nektar Therapeutics (NKTR) Thursday said the REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis met its primary goal.
The REZOLVE-AD study randomized patients with moderate-to-severe atopic dermatitis to receive either rezpegaldesleukin or a placebo. Rezpegaldesleukin demonstrated a statistically significant improvement over placebo on the primary endpoint, the mean change in Eczema Area and Severity Index (EASI) at week 16.
Nektar stock is more than 4% up this morning at $53.60.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.